Novo Nordisk (NOVO) investor relations material

Strategic Focus and Market Opportunity

• Focus on innovation in obesity, diabetes, and related comorbidities, addressing significant unmet needs globally.

• Over 550 million people live with diabetes and more than 900 million with obesity worldwide.

• Only ~1% of people with obesity are treated with branded anti-obesity medications.

Strategic Highlights and Product Performance

• Achieved over 3 million prescriptions for the new GLP-1/Wegovy pill within 22 weeks, with rapid acceleration and a 60% new-to-brand prescription share in the US AOM market.

• The pill's efficacy, tolerability, and less restrictive regimen drive strong physician and patient adoption, differentiating it from competitors.

• Recent launches include the UAE, with promising early data and plans for further global expansion.

• ADA 2026 featured 40 accepted abstracts, 36 presentations, and four oral presentations, covering over 15 clinical trials and showcasing innovation across semaglutide, CagriSema, Zenagamtide, UBT251, and more.

Clinical Development and Pipeline Updates

• CagriSema demonstrated up to 14.2% weight loss and 1.8–2.3% HbA1c reduction in T2D, with a safety profile comparable to semaglutide monotherapy and 42.8% achieving ≥15% weight loss.

• Higher dose CagriSema studies will be initiated, leveraging successful dose escalation of semaglutide to 7.2 mg.

• Zenagamtide showed up to 14.6% weight loss and 1.7% HbA1c reduction in T2D, with mostly mild to moderate GI events and ongoing phase 3 programs for obesity, diabetes, and comorbidities.

• UBT251 achieved up to 19.7% mean weight loss in a Chinese population, with over 48% achieving ≥20% weight loss, very low withdrawal rates, and global phase III trials planned.